Mineralys Therapeutics Presents New Post-Hoc Analysis from Target-HTN Phase 2 Trial of Lorundrostat in Late-Breaking Poster Session at ASN Kidney Week 2023 MeetingGlobeNewsWire • 11/02/23
Mineralys Therapeutics to Announce Third Quarter 2023 Financial Results and Host Conference Call on Tuesday, November 7, 2023GlobeNewsWire • 10/31/23
Mineralys Therapeutics Announces Upcoming Poster Presentations at Two Scientific Conferences in November 2023GlobeNewsWire • 10/13/23
Mineralys Therapeutics Expands its Board of Directors with Appointments of Glenn Sblendorio and Daphne KarydasGlobeNewsWire • 09/14/23
Mineralys Therapeutics to Participate in the Cantor Fitzgerald Global Healthcare Conference on Thursday, September 28, 2023GlobeNewsWire • 09/11/23
Mineralys Therapeutics Announces JAMA Publication of Full Target-HTN Phase 2 Trial Results for Lorundrostat in Uncontrolled and Treatment-Resistant HypertensionGlobeNewsWire • 09/10/23
Mineralys Therapeutics Presents Target-HTN Phase 2 Trial Results in Late-Breaking Science Session at 2023 AHA Hypertension Scientific SessionsGlobeNewsWire • 09/10/23
Mineralys Therapeutics Selected for Oral Poster Presentation of Target-HTN Phase 2 Trial Results at 2023 AHA Hypertension Scientific SessionsGlobeNewsWire • 09/05/23
Wall Street Analysts See a 199.3% Upside in Mineralys Therapeutics, Inc. (MLYS): Can the Stock Really Move This High?Zacks Investment Research • 09/05/23
Mineralys Therapeutics to Participate in the Wells Fargo Securities Healthcare Conference on Thursday, September 7, 2023GlobeNewsWire • 08/29/23
Mineralys Therapeutics, Inc. (MLYS) Loses -19.64% in 4 Weeks, Here's Why a Trend Reversal May be Around the CornerZacks Investment Research • 08/22/23
Mineralys Therapeutics Reports Second Quarter 2023 Financial Results and Provides Corporate UpdateGlobeNewsWire • 08/07/23
Mineralys Therapeutics to Announce Second Quarter 2023 Financial Results and Host Conference Call on Monday, August 7, 2023GlobeNewsWire • 07/31/23
Mineralys Therapeutics Announces Expansion of Planned Phase 2 Trial of Lorundrostat Alone and in Combination with SGLT2 Inhibitor to Treat Patients with Chronic Kidney Disease (CKD)GlobeNewsWire • 07/17/23
Mineralys Therapeutics Reports First Quarter 2023 Financial Results and Provides Corporate UpdateGlobeNewsWire • 05/15/23
Mineralys Therapeutics Announces First Patient Dosed in the ADVANCE-HTN Pivotal Trial of Lorundrostat for the Treatment of Uncontrolled and Resistant HypertensionGlobeNewsWire • 05/02/23
Mineralys Therapeutics to Announce First Quarter 2023 Financial Results and Host Conference Call on Monday, May 15, 2023GlobeNewsWire • 05/01/23
Mineralys Therapeutics to Participate in the Bank of America Securities 2023 Health Care Conference on Wednesday, May 10, 2023GlobeNewsWire • 04/27/23
Mineralys Therapeutics Reports Fourth Quarter and Full Year 2022 Financial Results and Provides Corporate UpdateGlobeNewsWire • 03/15/23
Mineralys Therapeutics Presents Positive Lorundrostat Results from the Phase 2 Target-HTN Trial at ACC.23/WCCGlobeNewsWire • 03/04/23